RESOURCES

Downloadable resources for healthcare professionals

Icon: pill bottle

OJJAARA HCP Brochure

An overview of the safety and efficacy of OJJAARA for healthcare professionals.

DOWNLOAD HCP BROCHURE

Icon: OJJAARA dosing guide

OJJAARA HCP Dosing Guide

A comprehensive resource of dosing information for OJJAARA.

DOWNLOAD HCP DOSING GUIDE

Icon: pill bottle

OJJAARA Dose Modification Program Brochure

The OJJAARA Dose Modification Program is available for patients who require a mid-cycle dose reduction of their current tablet strength. This brochure provides an overview and explains how to access the program for your eligible patients taking OJJAARA.

DOWNLOAD PROGRAM BROCHURE

Icon: OJJAARA dosing guide

OJJAARA Dose Modification Program Form

GSK offers a Dose Modification Program for patients who may require a mid-cycle dose change of their current OJJAARA tablet strength to a reduced tablet strength. Patients who require a tablet dose reduction may receive a 30-day supply of OJJAARA. To enroll your eligible OJJAARA patient, download the program enrollment form.

DOWNLOAD PROGRAM ENROLLMENT FORM

Support icon

Find support and savings information

TOGETHER WITH GSK ONCOLOGY

Efficacy icon

See the data for OJJAARA in JAKi-experienced patients

SEE THE OJJAARA DATA

JAKi=Janus kinase inhibitor.

For US Healthcare ProfessionalsFor US HCPs Visit US Patient Site GSK MedInfo Visit Patient Site
INDICATION AND IMPORTANT SAFETY INFORMATION
INDICATION

OJJAARA is indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.

OJJAARA is indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.

IMPORTANT SAFETY INFORMATION

Risk of Infections

  • Serious (including fatal) infections (e.g., bacterial and viral, including COVID-19) occurred in 13% of patients treated with OJJAARA. Infections regardless of grade occurred in 38% of patients. Delay starting therapy until active infections have resolved. Monitor patients for signs and symptoms of infection and initiate appropriate treatment promptly.

Risk of Infections

  • Serious (including fatal) infections (e.g., bacterial and viral, including COVID-19) occurred in 13% of patients treated with OJJAARA. Infections regardless of grade occurred in 38% of patients. Delay starting therapy until active infections have resolved. Monitor patients for signs and symptoms of infection and initiate appropriate treatment promptly.